Results 11 to 20 of about 18,522 (215)

Hubungan Rasio APO-B/APOA-I dengan Index Massa Tubuh

Jurnal Kesehatan, 2022
Body Mass Index (BMI) is a simple way to monitor weight. Overweight as a result of excessive body fat accumulation which is characterized by a decrease in HDL (High-Density Lipoprotein), namely the atherogenic side represented by levels of Apolipoprotein
Megawati Megawati, Liong Boy Kurniawan, Uleng Bahrun   +2 more
doaj   +3 more sources

Targeted Replacement of Mouse Apolipoprotein A-I with Human ApoA-I or the Mutant ApoA-IMilano [PDF]

Journal of Biological Chemistry, 2003
Despite a pro-atherogenic profile, individuals carrying the molecular variant (R173C) of apolipoprotein (apo)A-I, named apoA-I(Milano) (apoA-I(M)), appear to be at reduced risk for cardiovascular disease.
Cinzia Parolini, Giulia Chiesa, Yiwen Zhu, Trudy Forte, Silvia Caligari, Elisabetta Gianazza, Maria Grazia Sacco, Cesare R. Sirtori, Edward M. Rubin   +8 more
openaire   +3 more sources

Apolipoprotein A-I (CSL112) and Cardiovascular Outcomes in Atherosclerotic Cardiovascular Disease: A Scoping Review. [PDF]

Clin Cardiol
Apolipoprotein A‐I (ApoA‐I), the principal protein of HDL, plays a key role in reverse cholesterol transport, inflammation modulation, and plaque stabilization in atherosclerotic cardiovascular disease. Emerging ApoA‐I–based therapies, including CSL112, enhance cholesterol efflux capacity, though definitive reductions in cardiovascular events remain ...
Habib A, Khan MSM, Aneeq A, Tahir HMT, Mehmoodi A, Malik J, Perveen A.   +6 more
europepmc   +2 more sources

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism

Hepatology, EarlyView., 2022
Hepatic APOF transcript levels correlate inversely with plasma TG and hepatic steatosis in humans. ApoF expression in mice promotes VLDL‐TG production and lipoprotein remnant clearance in mice. Abstract Background NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD,
Audrey Deprince, Nathalie Hennuyer, Sander Kooijman, Amanda C. M. Pronk, Eric Baugé, Viktor Lienard, An Verrijken, Eveline Dirinck, Luisa Vonghia, Eloïse Woitrain, Niels J. Kloosterhuis, Eléonore Marez, Pauline Jacquemain, Justina C. Wolters, Fanny Lalloyer, Delphine Eberlé, Sandrine Quemener, Emmanuelle Vallez, Anne Tailleux, Mostafa Kouach, Jean‐Francois Goossens, Violeta Raverdy, Bruno Derudas, Jan Albert Kuivenhoven, Mikaël Croyal, Bart van de Sluis, Sven Francque, François Pattou, Patrick C. N. Rensen, Bart Staels, Joel T. Haas   +30 more
wiley   +1 more source

Tangier disease: a structural defect in apolipoprotein A-I (apoA-I Tangier). [PDF]

Proceedings of the National Academy of Sciences, 1982
Tangier disease is a familial disorder characterized by orange tonsils, cholesterol ester deposition in reticuloendothelial cells, abnormal chylomicron remnants, and a marked reduction in high density lipoproteins. Plasma concentrations of the apolipoproteins apo-A-I and apoA-II in patients with Tangier disease are approximately 1% and 7% of those in ...
L L, Kay, R, Ronan, E J, Schaefer, H B, Brewer   +3 more
openaire   +2 more sources

Correlation between Pretreatment Serum Apolipoprotein Level and Prognosis of Small Cell Lung Cancer Patients

Chinese Journal of Lung Cancer, 2020
Background and objective Lung cancer is the leading cause of cancer-related death, and small cell lung cancer (SCLC) has a poor prognosis in all types of lung cancer.
Ya DONG, Haocheng WANG, Dongfeng SHAN, Linwei ZHANG, Zhuang YU   +4 more
doaj   +1 more source

Elevated ApoB/ApoA-I ratio is associated with acute anti-N-Methyl-D-aspartate receptor encephalitis, but not disease outcomes

Frontiers in Neurology, 2022
ObjectiveThe purpose of the present study is to clarify the relationship between the apolipoprotein B100/apolipoprotein A-I (ApoB/ApoA-I) ratio and anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis.MethodsA total of 71 patients with anti-NMDAR
Yingying Liu, Xiaomeng Ma, Lili Ma, Zhumin Su, Donghong Li, Xiaohong Chen   +5 more
doaj   +1 more source

Apolipoprotein A-I Modulates Regulatory T Cells in Autoimmune LDLr−/−, ApoA-I−/− Mice [PDF]

Journal of Biological Chemistry, 2010
The immune system is complex, with multiple layers of regulation that serve to prevent the production of self-antigens. One layer of regulation involves regulatory T cells (Tregs) that play an essential role in maintaining peripheral self-tolerance. Patients with autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis have ...
Ashley J, Wilhelm, Manal, Zabalawi, John S, Owen, Dharika, Shah, Jason M, Grayson, Amy S, Major, Shaila, Bhat, Dwayne P, Gibbs, Michael J, Thomas, Mary G, Sorci-Thomas   +9 more
openaire   +2 more sources

Differential tissue-specific expression of human apoA-I and apoA-II

Journal of Lipid Research, 1991
To evaluate the sources of high density lipoprotein (HDL) particles containing only apolipoprotein A-I (apoA-I), the synthesis of apoA-I and apolipoprotein A-II (apoA-II) was examined in human liver and small intestine as well as the human intestinally ...
TL Eggerman, JM Hoeg, MS Meng, A Tombragel, D Bojanovski, HB Brewer, Jr   +5 more
doaj   +1 more source

The Association between Apolipoprotein A-II and Metabolic Syndrome in Korean Adults: A Comparison Study of Apolipoprotein A-I and Apolipoprotein B [PDF]

Diabetes & Metabolism Journal, 2012
BackgroundApolipoprotein A-II (apoA-II) is the second-most abundant apolipoprotein in human high-density lipoprotein and its role in cardio metabolic risk is not entirely clear.
Dong Won Yi, Dong Wook Jeong, Sang Yeoup Lee, Seok Man Son, Yang Ho Kang   +4 more
doaj   +1 more source